Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 25 of 42 entries
View as:

Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01426880 Org: User:
Start: 08/31/11 End: 08/31/13 Due: 08/31/14

Study in Elderly Patients With Early Breast Cancer (ICE)

Phase: N/A Priority: Normal
NCT ID: NCT00196859 Org: User:
Start: 06/30/04 End: 01/31/14 Due: 01/31/15

Efficacy and Safety of Cabazitaxel Versus Weekly Paclitaxel as Neo-adjuvant Treatment in Patients With Triple Negative or Luminal B/HER2 Normal BC (GENEVIEVE)

Phase: N/A Priority: Normal
NCT ID: NCT01779479 Org: User:
Start: 02/28/13 End: 02/29/16 Due: 02/28/17

Pazopanib in Combination With Capecitabine in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01498458 Org: User:
Start: 10/31/10 End: 05/31/14 Due: 05/31/15

Denosumab as an add-on Neoadjuvant Treatment (GeparX)

Phase: N/A Priority: Normal
NCT ID: NCT02682693 Org: User:
Start: 02/13/17 End: 12/31/20 Due: 12/31/21

Neoadjuvant Chemotherapy Including Sorafenib in Women With Previously Untreated Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00548899 Org: User:
Start: 11/30/07 End: 12/31/11 Due: 12/31/12

German Preoperative Adriamycin Docetaxel Study

Phase: N/A Priority: Normal
NCT ID: NCT00543829 Org: User:
Start: 04/30/98 End: 06/30/99 Due: 06/30/00

Combination Chemotherapy With or Without Capecitabine and/or Trastuzumab Before Surgery in Treating Women With Stage I, Stage II, or Stage III Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00288002 Org: User:
Start: 01/31/05 End: - Due: -

Bevacizumab, Everolimus (RAD001), and Lapatinib as Neoadjuvant Chemotherapy Regimes for Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00567554 Org: User:
Start: 10/31/07 End: 10/31/15 Due: 10/31/16

A Randomized Study to Determine the Efficacy of a Taxane and Bevacizumab With or Without Capecitabine as First Line Chemotherapy in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01200212 Org: User:
Start: 07/31/09 End: 10/31/12 Due: 10/31/13

A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto)

Phase: N/A Priority: Normal
NCT ID: NCT02125344 Org: User:
Start: 12/31/14 End: 01/30/17 Due: 01/30/18

Docetaxel, Doxorubicin and Cyclophosphamide Versus Vinorelbine and Capecitabine in Patients Not Sufficiently / Sufficiently Responding as Preoperative Treatment of Locally Advanced or Operable Primary Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00544765 Org: User:
Start: 09/30/02 End: 02/29/08 Due: 02/28/09

Breast Cancer in Pregnancy Register Study

Phase: N/A Priority: Normal
NCT ID: NCT00196833 Org: User:
Start: 04/30/03 End: 04/30/26 Due: 04/30/27

A Multicentre Phase I-II Study to Investigate the Combination of Bendamustine With Weekly Paclitaxel as First or Second Line Therapy in Patients With Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00661739 Org: User:
Start: 07/31/05 End: 05/31/11 Due: 05/31/12

Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)

Phase: N/A Priority: Normal
NCT ID: NCT01583426 Org: User:
Start: 07/31/12 End: 12/31/18 Due: 12/31/19

Tamoxifen +/- GnRH Analogue vs Aromatase Inhibitor + GnRH Analogue in Male Breast Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT01638247 Org: User:
Start: 08/31/12 End: 05/31/18 Due: 05/31/19

Efficacy of RAD001 in Breast Cancer Patients With Bone Metastases

Phase: N/A Priority: Normal
NCT ID: NCT00466102 Org: User:
Start: 12/31/06 End: 12/31/12 Due: 12/31/13

A Study of Palbociclib in Addition to Standard Endocrine Treatment in Hormone Receptor Positive Her2 Normal Patients With Residual Disease After Neoadjuvant Chemotherapy and Surgery

Phase: N/A Priority: Normal
NCT ID: NCT01864746 Org: User:
Start: 10/30/13 End: 12/21/20 Due: 12/21/21

Preoperative Epirubicin Paclitaxel Aranesp Study (PREPARE)

Phase: N/A Priority: Normal
NCT ID: NCT00544232 Org: User:
Start: 08/31/02 End: 09/30/06 Due: 09/30/07

Everolimus Beyond Progress for Patients Who Had Progress Under Everolimus and Exemestane

Phase: N/A Priority: Normal
NCT ID: NCT01773460 Org: User:
Start: 07/31/13 End: 07/31/14 Due: 07/31/15

Addition of PD-L1 Antibody MEDI4736 to a Taxane-anthracycline Chemotherapy in Triple Negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02685059 Org: User:
Start: 06/30/16 End: 03/31/18 Due: 03/31/19

Mono Efficacy of Capecitabine (MoniCa)

Phase: N/A Priority: Normal
NCT ID: NCT00196820 Org: User:
Start: 07/31/05 End: 12/31/08 Due: 12/31/09

Capivasertib Plus Fulvestrant vs. Fulvestrant in Primary High-risk Lobular Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06607757 Org: User:
Start: 12/04/24 End: 08/31/26 Due: 08/31/27

Neoadjuvant Endocrine Therapy +/- the PI3K Inhibitor Inavolisib in HER2+, HR+, PIK3CA Mutant Early Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05306041 Org: User:
Start: 01/02/23 End: 01/31/27 Due: 01/31/28

Dose EScalation Induction of EvERolimus

Phase: N/A Priority: Normal
NCT ID: NCT02387099 Org: User:
Start: 05/31/15 End: 07/31/21 Due: 07/31/22